Moderna made a lot of money during the pandemic, but its post-pandemic prospects look bleak. Sales in 2025 could be down more than half from 2024 levels, according to Moderna's latest guidance ...

In my search, I’ve discovered a few things: Consistency matters. A thinner lotion might cut it in warmer climates, but if you’re trying to really moisturize, something with a bit of heft and ...

Moderna Inc. shares plunged after the company slashed its sales forecast for this year as it struggles with slow demand for its Covid and RSV vaccines. The Cambridge, Massachusetts-based company ...

Moderna projects $1.5 billion-$2.5 billion in 2025 revenue, with cash and investments estimated at $6 billion by year-end. 2024 product sales are approximately $3 billion-$3.1 billion, driven by $ ...

Moderna’s stock price has dropped about 60% in the past 12 months. Facing this set of challenges, Moderna in September laid out a plan to cut annual R&D spending by more than 20%, or $1.1 ...

You may be able to get away with using a lighter lotion in the summer, especially if it does have powerful hydrating ingredients, but typically for those who have year-round dryness or a condition ...

Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...

Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of ...

Moderna stock (MRNA) fell over 9% on Wednesday, forfeiting most of its gains from Tuesday's session during a volatile week for the stock seen after the first reported bird flu death in the US ...

Products are independently selected by our editors. We may earn an affiliate commission from links. I have a confession: I hoard the best scented body lotions. But I mean, can you blame me? These ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have been sliding down over the past few years due to waning demand for the ...